Stable Huh-7 cell lines expressing non-structural proteins of genotype 1a of hepatitis C virus

Shahid, Imran; Gull, Sana; Ijaz, Bushra; Ahmad, Waqar; Ansar, Muhammad; Asad, Sultan; Kausar, Hina; Sarwar, Muhammad Tahir; Khan, Muhammad Kazim; Hassan, Sajida

doi:10.1016/j.jviromet.2013.01.005

Cited by 10 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C Virus (HCV) is a major global disease that frequently causes chronicity and has the potential to cause liver failure. Numerous complications brought on by the hepatitis C virus (HCV) infection, including liver failure, cirrhosis, hepatocellular carcinoma (HCC), and other; result in thousands of deaths each year [1]& [2]. For its morbidity and mortality, The World Health Organization (WHO) considered HCV as one of its priorities in the field of infectious diseases, in Egypt, also HCV infection is always on the landscape of the ministry of health, as Egypt is a country with the highest rate of HCV infection, accounting for about 10% of the population [3]& [4].…”

Section: Introductionmentioning

confidence: 99%

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Ibrahim

soliman

Elsaied

2023

International Journal of Theoretical and Applied Research

View full text Add to dashboard Cite

Hepatic, renal, and immune system impairment are associated with chronic hepatitis C virus (HCV) infection. This study looked at how some hepatic and renal functions in HCV patients were impacted by treatment with direct acting antivirals (DAAs). Six hundred male and female Egyptian patients with HCV infection who received three months of sofosbuvir/daclatasvir combined therapy and were primarily identified by anti-HCV antibodies were prospectively enrolled. This study measured peripheral blood hematological parameters, pre-and post-treatment serum HCV RNA viral load, alpha-fetoprotein, ALT, AST, total bilirubin, creatinine, and other parameters. Three months of sofosbuvir/daclatasvir combined therapy resulted in SVR in 100% of patients. Blood hemoglobin, platelets count, neutrophils%, and eosinophil% were all significantly higher after treatment, whereas post-treatment HCV RNA viral load, alpha-fetoprotein ALT, AST, total bilirubin, creatinine, total leucocyte count, lymphocytes percent, and monocytes percent were all significantly lower. This study's findings suggest that DAAs sofosbuvir/daclatasvir combined therapy for three months has a significant impact on biochemical, immunological, and hematological parameters, suggesting clinically significant findings in patients with CHC who have been successfully treated.

show abstract

Section: Introductionmentioning

confidence: 99%

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Ibrahim

soliman

Elsaied

2023

International Journal of Theoretical and Applied Research

View full text Add to dashboard Cite

show abstract

“…Hepatitis C virus, one of the most common chronic diseases in the world, also has the potential to lead to liver failure. Each year, thousands of people die as a result of various HCV infection-related complications, such as liver failure, cirrhosis, hepatocellular carcinoma (HCC), and others [1,2].…”

Section: Introductionmentioning

confidence: 99%

Correlation of Serum Hepatitis C Viral Load and Immunobiochemical biomarkers in Combined Therapy Treated Patients

Ibrahim,

soliman,

Elsaied

2023

International Journal of Theoretical and Applied Research

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major global disease that frequently causes chronicity and can potentially cause liver failure and is widespread in Egypt. The current study aimed to explore the potential correlation between quantitatively detected virus C load using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay and some immunological, biochemical, and hematological biomarkers. Results from 600 HCV-positive people ranging between the age of 25 and 55 years old were analyzed using Prism, a computer (Graph Pad software. Version 5, San Diego, CA), and concluded that; there was a significant relation between HCV viral load and immuno-biological biomarkers. Also, the present study referred to the efficacy of Sofosbuvir/Daclatasvir combined therapy where 100% Sustained Virological Response (SVR) in all patients.

show abstract

“…The regional prevalence for HCV varies substantially around the world, where the infection presents the state of universal coverage in East and South Asia (e.g., in Egypt, the prevalence is as high as 22 %) to no access at all to others (i.e., some North American and European countries) [1,2]. The new incidents of chronic HCV infection are increasing 3-4 million every year without previous ascertainment of HCV risk, and it seems tough to determine because many acute HCV cases are not noticed clinically [2,3]. Analogously, acute HCV infection, a multifaceted disease is often asymptomatic or sometimes linked with nonspecific symptoms that lead to chronic hepatitis C in 80 % of infected individuals [4].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies

Shahid¹,

Almalki²,

AlRabia³

et al. 2017

Advances in Treatment of Hepatitis C and B

Self Cite

View full text Add to dashboard Cite

The advancement in hepatitis C virus (HCV) therapeutics has been profoundly enhanced by an improved understanding of viral life cycle in host cells, development of novel direct-acting antivirals (DAAs), and exploring other emerging treatment paradigms on the horizon. The approvals of first-, second-, and next-wave direct-acting antivirals highlight the swift pace of progress in the successful development of an expanding variety of therapeutic regimens for use in patients with chronic hepatitis C virus infection. Triple or quadruple therapies based on a combination of different direct-acting antivirals with or without pegylated interferon (IFN) and ribavirin (RBV) have raised the hopes to improve the current treatment strategies for other difficult-to-treat individuals. The development of more efficacious, well-tolerated, and cost-effective interferons with a low frequency of adverse events and short treatment durations is also in the pipeline. An experimental protective vaccine against hepatitis C virus demonstrated promise in preliminary human safety trials, and a larger phase II clinical trials are under consideration to further determine the efficacy of the vaccine. This pragmatic book chapter discusses the current state of knowledge in hepatitis C virus therapeutics and provides a conceptual framework of emerging and investigational treatment strategies directed against this silent epidemic.

show abstract

Stable Huh-7 cell lines expressing non-structural proteins of genotype 1a of hepatitis C virus

Cited by 10 publications

References 26 publications

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Correlation of Serum Hepatitis C Viral Load and Immunobiochemical biomarkers in Combined Therapy Treated Patients

Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies

Contact Info

Product

Resources

About